(P116) Pain and Radiographic Control After Stereotactic Radiosurgery for Spinal Metastases From Hepatocellular Carcinoma: A Comparison With Other Radioresistant Histologies

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

When treated with SRS to the spine, metastatic HCC has worse pain and radiographic control than other highly radioresistant histologies, suggesting that HCC should be included in the category of highly radioresistant tumors. Whether these lesions may benefit from further dose escalation and/or alternate treatment strategies will be the subject of future studies.

Todd J. Carpenter, MD, Michael H. Buckstein, MD, PhD, Eddie Zhang, BS, Seth Blacksburg, MD, MBA, Isabelle M. Germano, MD, Sheryl Green, MBBCH; Department of Radiation Oncology, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai; Department of Radiation Oncology, Winthrop University Hospital

PURPOSE: We sought to determine the relative radioresistance of hepatocellular carcinoma (HCC) by evaluating the clinical efficacy of stereotactic radiosurgery (SRS) for spinal metastases from HCC compared with outcomes in patients with classically radioresistant histologies in terms of local control (LC) and pain control.

MATERIALS AND METHODS: We performed a retrospective review of all patients treated at our institution with spine SRS for metastatic HCC, renal cell carcinoma, melanoma, and sarcoma from January 2007 through May 2014. Radiographic control and patient-reported pain control were analyzed as a function of various patient- and treatment-related parameters.

RESULTS: Of 134 lesions in 96 patients treated with spine SRS during the study period, 41 were radioresistant histologies, including 18 HCC, 1 mixed HCC/cholangiocarcinoma, 15 renal cell carcinoma, 6 melanoma, and 1 leiomyosarcoma. Median age was 61 years. Extraosseous disease was present in 63% overall (74% and 55% in HCC and non-HCC patients, respectively; P = NS). Spinal cord compression was present in 29% (32% and 27% in HCC and non-HCC patients, respectively; P = NS), and 24% had decompressive surgery prior to SRS (26% and 23% in HCC and non-HCC patients, respectively; P = NS). Median dose was 18 Gy (range: 14–18 Gy), with no difference between groups. Follow-up imaging was available for 35 patients. With a median follow-up of 6.4 months, actuarial 3-, 6-, and 12-month LC rates for HCC and non-HCC patients were 74%, 65%, and 35% and 94%, 94%, and 85%, respectively (P = .0383). Median time to local failure was 3.5 months for HCC patients and 10.7 months for non-HCC patients. On multivariate analysis (MVA), there was significantly worse LC with HCC histology (P = .0257). Of the 29 patients reporting pretreatment pain, initial pain relief was achieved in 27 (93%); both patients who did not experience initial pain relief had HCC. Actuarial 3-, 6-, and 12-month pain control rates for HCC and non-HCC patients were 73%, 61%, and 23% and 100%, 90%, and 90%, respectively (P = .0405). This interaction remained significant on MVA (P = .0414).

CONCLUSIONS: When treated with SRS to the spine, metastatic HCC has worse pain and radiographic control than other highly radioresistant histologies, suggesting that HCC should be included in the category of highly radioresistant tumors. Whether these lesions may benefit from further dose escalation and/or alternate treatment strategies will be the subject of future studies.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Related Content